|
WO2021057910A1
|
|
Peptidylarginine deiminase inhibitor and use thereof
|
|
WO2021057782A1
|
|
Heterocyclic derivative and use thereof
|
|
WO2020187165A1
|
|
Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
|
|
CN111658653A
|
|
Use of phosphodiesterase inhibitors
|
|
CN111471059A
|
|
PDE9 inhibitors and uses thereof
|
|
CN111471037A
|
|
Allylamine compound and application thereof
|
|
WO2020143763A1
|
|
Haloallylamine compounds and application thereof
|
|
WO2020143626A1
|
|
Pde9 inhibitor and use thereof
|
|
AU2019323455A1
|
|
Novel quinoline derivative inhibitor
|
|
CN112135826A
|
|
Amino-norbornane derivative and preparation method and application thereof
|
|
CN110498769A
|
|
IDO inhibitor and application
|
|
CN110357888A
|
|
Heterocycle phosphodiesterase inhibitors and application thereof
|
|
CN110386921A
|
|
Fibroblast growth factor acceptor inhibitor compound
|
|
US2020407370A1
|
|
Peptidylarginine deiminase inhibitor and use thereof
|
|
CN110194770A
|
|
Peptide acyl arginine deiminase inhibitor and application thereof
|
|
WO2019141202A1
|
|
Tam family kinase /and csf1r kinase inhibitor and use thereof
|
|
CN109810041A
|
|
Halogenated allyl amine SSAO/VAP-1 inhibitor and its application
|
|
CN109776517A
|
|
Heterocyclic indole amine 2,3-dioxygenase inhibitor
|
|
CN109721620A
|
|
HPK1 inhibitor and application thereof
|
|
CA3077134A1
|
|
Pde9 inhibitor and use thereof
|
